Ann: EBR Systems Investor Roadshow, page-7

As @longreach guessed, separate meetings with institutional investors were planned for this visit. According to JM (over drinks) they are all supportive of EBR’s mission, and so are the original large stake holders since before the IPO. I suggested to JM none of these guys are interested in just doubling their money and he agreed. It is glaringly obvious EBR’s value proposition will attract interest from the existing players in the pacemaker industry. One questioner at the meeting last night couldn’t get his head around the fact no wireless left ventricle solution has been developed by the big boys. This seems to be the case, as you can’t hide trials from the public.

The guest speaker was a failed candidate from an existing cardiac resynchronisation therapy (because the wires created problems). Richard couldn’t understand how the old school method can possibly be allowed to continue if EBR’s solution is ticked off by the FDA.

DYOR and get to a meeting if possible!